| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The rise in S1P3 client dependency in [Ca2+]i is inhibited by TY-52156[1]. Submicromolar potency and a strong reliance on the S1P3 client are displayed by TY-52156 [1]. 10 μM; 10 min) TY-52156
|
|---|---|
| ln Vivo |
Following lipid in vivo, TY-52156 (10 mg/kg, 30 mg/kg; sidewall) reduces the S1P3 receptor-induced bradycardia [1].
|
| Cell Assay |
Western Blot analysis [1]
Cell Types: Chinese Hamster Ovary K1 cells Tested Concentrations: 10 μM Incubation Duration: 10 min Experimental Results: Inhibits S1P-induced p44/p42 MAPK phosphorylation. ) Inhibits S1P-induced p44/p42 MAPK phosphorylation. |
| Animal Protocol |
Animal/Disease Models: Male SD rat (290–340 g) [1]
Doses: 10 mg/kg, 30 mg/kg Route of Administration: Oral Experimental Results:In vivo oral administration can inhibit S1P3 receptor-induced bradycardia. |
| References | |
| Additional Infomation |
TY 52156 is an imidohydrazide resulting from the formal condensation of the hydrazide carbonyl group of N'-(p-chlorophenyl)-3,3-dimethyl-2-oxobutanehydrazide with the amino group of p-chloroaniline. A potent and selective antagonist of sphingosine-1-phosphate receptor 3 (S1PR3). It has a role as a sphingosine-1-phosphate receptor 3 antagonist. It is a member of monochlorobenzenes and an imidohydrazide.
|
| Molecular Formula |
C18H19CL2N3O
|
|---|---|
| Molecular Weight |
364.27
|
| Exact Mass |
363.091
|
| CAS # |
934369-14-9
|
| PubChem CID |
16046248
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.592
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
446
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XONRRGIRSGNWFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H19Cl2N3O/c1-18(2,3)16(24)17(21-14-8-4-12(19)5-9-14)23-22-15-10-6-13(20)7-11-15/h4-11,22H,1-3H3,(H,21,23)
|
| Chemical Name |
N-(4-chloroanilino)-N'-(4-chlorophenyl)-3,3-dimethyl-2-oxobutanimidamide
|
| Synonyms |
TY52156; TY 52156; TY-52156
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~274.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7452 mL | 13.7261 mL | 27.4522 mL | |
| 5 mM | 0.5490 mL | 2.7452 mL | 5.4904 mL | |
| 10 mM | 0.2745 mL | 1.3726 mL | 2.7452 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
